IN2014MN01469A - - Google Patents

Info

Publication number
IN2014MN01469A
IN2014MN01469A IN1469MUN2014A IN2014MN01469A IN 2014MN01469 A IN2014MN01469 A IN 2014MN01469A IN 1469MUN2014 A IN1469MUN2014 A IN 1469MUN2014A IN 2014MN01469 A IN2014MN01469 A IN 2014MN01469A
Authority
IN
India
Prior art keywords
derivative
modulation
processes
formula
preparation
Prior art date
Application number
Other languages
English (en)
Inventor
David R Witty
David T Macpherson
Gerard M P Giblin
Steven J Stanway
Original Assignee
Convergence Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Convergence Pharmaceuticals filed Critical Convergence Pharmaceuticals
Publication of IN2014MN01469A publication Critical patent/IN2014MN01469A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • A61P23/02Local anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IN1469MUN2014 2011-12-22 2012-12-21 IN2014MN01469A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161579613P 2011-12-22 2011-12-22
GBGB1122113.2A GB201122113D0 (en) 2011-12-22 2011-12-22 Novel compounds
PCT/GB2012/053233 WO2013093496A1 (fr) 2011-12-22 2012-12-21 Composé 2-(pyridin-2yl)-1,7-diaza-spiro[4.4]nonane-6-one comme modulateur des canaux sodiques voltage-dépendants

Publications (1)

Publication Number Publication Date
IN2014MN01469A true IN2014MN01469A (fr) 2015-04-17

Family

ID=45572877

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1469MUN2014 IN2014MN01469A (fr) 2011-12-22 2012-12-21

Country Status (18)

Country Link
US (3) US9303032B2 (fr)
EP (2) EP2797922B1 (fr)
JP (2) JP2015502394A (fr)
KR (1) KR20140113692A (fr)
CN (1) CN104271581B (fr)
AU (1) AU2012356386A1 (fr)
BR (1) BR112014014940A2 (fr)
CA (1) CA2858938C (fr)
EA (1) EA026500B1 (fr)
ES (1) ES2581327T3 (fr)
GB (1) GB201122113D0 (fr)
HK (2) HK1203492A1 (fr)
IL (1) IL233215A0 (fr)
IN (1) IN2014MN01469A (fr)
MX (1) MX2014007637A (fr)
SG (1) SG11201403356YA (fr)
WO (2) WO2013093496A1 (fr)
ZA (1) ZA201404269B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201122113D0 (en) 2011-12-22 2012-02-01 Convergence Pharmaceuticals Novel compounds
GB201209015D0 (en) * 2012-05-22 2012-07-04 Convergence Pharmaceuticals Novel compounds
RU2650523C1 (ru) * 2017-07-24 2018-04-16 федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) Производное пиридоксина для лечения эпилепсии
MA50371A (fr) * 2017-10-10 2021-03-31 Biogen Inc Procédé de préparation de dérivés spiro
RU2761436C1 (ru) 2017-11-17 2021-12-08 Целликс Био Прайвет Лимитед Композиции и способы лечения нарушений со стороны органа зрения
CN113563258A (zh) * 2021-07-29 2021-10-29 派普医药(江苏)有限公司 一种4-溴-2-(二氟甲基)-5-甲基吡啶的制备方法
WO2023044364A1 (fr) 2021-09-15 2023-03-23 Enko Chem, Inc. Inhibiteurs de protoporphyrinogène oxydase

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
WO1996025405A1 (fr) 1995-02-13 1996-08-22 G.D. Searle & Co. Isoxazoles substitues utilisables dans le traitement d'inflammations
UA57002C2 (uk) 1995-10-13 2003-06-16 Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування
GEP20032998B (en) 1996-04-12 2003-06-25 Searle & Co Substituted Benzenesulfonamide Derivatives as Prodrugs of Cox-2 Inhibitors
DE69724788T2 (de) 1996-07-18 2004-08-05 Merck Frosst Canada & Co., Halifax Substituierte pyridine als selektive cyclooxygenase inhibitoren
CO4960662A1 (es) 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
ES2231757T3 (es) 1997-09-05 2005-05-16 Glaxo Group Limited Composiciones farmaceutica que comprenden derivados de 2,3-diaril-pirazolo (1,5-b) piridazina.
DE69919887T2 (de) 1998-11-03 2005-09-15 Glaxo Group Ltd., Greenford Pyrazolopyridin derivative als selektive cox-2 inhibitoren
US6025683A (en) 1998-12-23 2000-02-15 Stryker Corporation Motor control circuit for regulating a D.C. motor
EP1157025B1 (fr) 1999-02-27 2004-03-10 Glaxo Group Limited Pyrazolopyridines
GB0003224D0 (en) 2000-02-11 2000-04-05 Glaxo Group Ltd Chemical compounds
GB0021494D0 (en) 2000-09-01 2000-10-18 Glaxo Group Ltd Chemical comkpounds
GB0323204D0 (en) 2003-10-03 2003-11-05 Novartis Ag Organic compounds
SE0302811D0 (sv) * 2003-10-23 2003-10-23 Astrazeneca Ab Novel compounds
US8143306B2 (en) 2005-10-10 2012-03-27 Convergence Pharmaceuticals Limited Methods of treating bipolar disorders
DE602006015215D1 (de) 2005-10-10 2010-08-12 Glaxo Group Ltd Prolinamidderivate als natriumkanalmodulatoren
TW200730494A (en) 2005-10-10 2007-08-16 Glaxo Group Ltd Novel compounds
TW200728258A (en) 2005-10-10 2007-08-01 Glaxo Group Ltd Novel compounds
GB0520578D0 (en) * 2005-10-10 2005-11-16 Glaxo Group Ltd Novel compounds
US7505330B2 (en) * 2006-08-31 2009-03-17 Micron Technology, Inc. Phase-change random access memory employing read before write for resistance stabilization
GB0701366D0 (en) * 2007-01-24 2007-03-07 Glaxo Group Ltd Novel pharmaceutical compositions
CA2676357A1 (fr) 2007-01-24 2008-07-31 Glaxo Group Limited Nouvelles compositions pharmaceutiques
GB0701365D0 (en) 2007-01-24 2007-03-07 Glaxo Group Ltd Novel pharmaceutical compositions
GB0706630D0 (en) 2007-04-04 2007-05-16 Glaxo Group Ltd Novel compounds
PL2477964T3 (pl) 2009-09-14 2015-08-31 Convergence Pharmaceuticals Proces wytwarzania pochodnych alfa-karboksyamidu
PE20121350A1 (es) * 2009-10-14 2012-10-20 Xenon Pharmaceuticals Inc Metodos sinteticos para compuestos espiro-oxoindol
GB201122113D0 (en) 2011-12-22 2012-02-01 Convergence Pharmaceuticals Novel compounds
GB201209015D0 (en) 2012-05-22 2012-07-04 Convergence Pharmaceuticals Novel compounds

Also Published As

Publication number Publication date
US20160185758A1 (en) 2016-06-30
JP2015502394A (ja) 2015-01-22
US9303032B2 (en) 2016-04-05
EP2794612A1 (fr) 2014-10-29
MX2014007637A (es) 2014-09-26
CA2858938A1 (fr) 2013-06-27
EP2794612B1 (fr) 2016-04-06
CA2858938C (fr) 2020-03-10
HK1203501A1 (en) 2015-10-30
AU2012356386A1 (en) 2014-07-10
US20150225400A1 (en) 2015-08-13
US9376436B2 (en) 2016-06-28
KR20140113692A (ko) 2014-09-24
US20140350040A1 (en) 2014-11-27
HK1203492A1 (en) 2015-10-30
CN104271581B (zh) 2016-08-31
SG11201403356YA (en) 2014-07-30
WO2013093497A1 (fr) 2013-06-27
CN104271581A (zh) 2015-01-07
EA201491251A1 (ru) 2014-11-28
ES2581327T3 (es) 2016-09-05
GB201122113D0 (en) 2012-02-01
ZA201404269B (en) 2016-06-29
JP2015502395A (ja) 2015-01-22
EA026500B1 (ru) 2017-04-28
EP2797922B1 (fr) 2016-04-06
IL233215A0 (en) 2014-08-31
EP2797922A1 (fr) 2014-11-05
WO2013093496A1 (fr) 2013-06-27
BR112014014940A2 (pt) 2017-06-13

Similar Documents

Publication Publication Date Title
PH12015502839B1 (en) Antiviral compounds
PH12016502132A1 (en) Aryl-or heteroaryl-substituted benzene compounds
IN2014MN02459A (fr)
MX344530B (es) Compuestos de benceno substituido.
IN2014MN01469A (fr)
EA028156B9 (ru) Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов
MX369388B (es) Moduladores heterociclicos de sintesis lipidica.
GEP201706695B (en) Substituted 4-phenyl-pyridi-nes for the treatment of nk-1 receptor related diseases
PH12013502565A1 (en) Substituted imidazopyridinyl-aminopyridine compounds
IN2014MN00988A (fr)
MX2013014843A (es) Oxazepinas como moduladores del canal de iones.
MX346375B (es) Antagonistas de espiro-oxindol de mdm2.
JO3773B1 (ar) معدلات p2x7
NZ705213A (en) C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
MX2014007897A (es) Nuevos derivados de azetidina, composiciones farmaceuticas y sus usos.
IN2015DN01151A (fr)
GEP20156372B (en) Pyridazinone compounds and their use as daao inhibitors
IN2014DN06104A (fr)
MX2015003701A (es) Composiciones para tratamiento.
MX2014002446A (es) Compuestos de ciclohexano sustituidos novedosos.
IN2014MN02393A (fr)
IN2015DN00085A (fr)
MX347541B (es) Analogos de acido sialico.
MX2013006670A (es) Derivado de 2-carboxamida-4-piperazinil-benzofurano.
NZ720807A (en) Fused heterocyclic compounds as ion channel modulators